Ultragenyx Pharmaceutical Inc.
RARENasdaq
$29.28
↓ -3.1%Jul 17 close · end-of-day
Price
1Y↑ +7.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.9B
Enterprise Value
$2.5B
P/E
—
P/S
4.4
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-17.1%
Dividend Yield
—
Revenue (TTM)
$670.0M
Net Income (TTM)
-$609.0M
Free Cash Flow (TTM)
-$503.0M
Gross Margin
—
Operating Margin
-83.7%
Net Margin
-90.9%
ROE
258.0%
ROIC
—
Debt / Equity
—
Net Cash
$413.0M
Return 1Y
+6.8%
Company profile
Ultragenyx Pharmaceutical Inc. focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the. treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia.
- CEO
- Emil D. Kakkis
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,310
- Headquarters
- California
- Website
- ultragenyx.com
Management & directors
- Horn HowardChief Financial Officer
- Parschauer Karah HerdmanEVP and Chief Legal Officer
- Crombez EricEVP and Chief Medical Officer
- Huizenga Theodore AlanSVP, Chief Accounting Officer
- Harris ErikEVP & Chief Commercial Officer
- Huang Dennis KarlSee Remarks
- Kakkis Emil DPresident & CEO
- Pinion John RichardSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
RARE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$136.0M↓ -2.2%
Diluted EPS-$1.84↑ +17.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $271.0M | $351.4M | $363.3M | $434.0M | $560.0M | $673.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$330.1M | -$381.7M | -$648.9M | -$569.0M | -$536.0M | -$535.0M |
| Net income | -$186.6M | -$454.0M | -$707.4M | -$607.0M | -$569.0M | -$575.0M |
| Diluted EPS | -$3.07 | -$6.70 | -$10.12 | -$8.25 | -$6.29 | -$5.83 |
| Operating cash flow | -$132.2M | -$338.7M | -$380.5M | -$475.0M | -$414.0M | -$466.0M |
| Free cash flow | -$176.1M | -$411.8M | -$496.6M | -$519.0M | -$421.0M | -$472.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -121.8% | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
| Net margin | -68.8% | -129.2% | -194.7% | -139.9% | -101.6% | -85.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $147.0M | $139.5M | $164.6M | $139.0M | $166.5M | $159.9M | $207.6M | $136.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$116.4M | -$132.0M | -$122.3M | -$143.0M | -$107.9M | -$170.9M | -$113.2M | -$169.0M |
| Net income | -$131.6M | -$133.5M | -$133.2M | -$151.0M | -$115.0M | -$180.4M | -$128.6M | -$185.0M |
| Diluted EPS | -$1.52 | -$1.40 | -$1.34 | -$1.57 | -$1.17 | -$1.81 | -$1.28 | -$1.84 |
| Operating cash flow | -$77.0M | -$67.0M | -$79.3M | -$166.0M | -$108.7M | -$91.4M | -$99.8M | -$197.0M |
| Free cash flow | -$79.0M | -$68.6M | -$79.5M | -$167.0M | -$111.5M | -$92.7M | -$100.8M | -$198.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -79.1% | -94.6% | -74.3% | -102.9% | -64.8% | -106.9% | -54.5% | -124.3% |
| Net margin | -89.5% | -95.7% | -80.9% | -108.6% | -69.0% | -112.8% | -62.0% | -136.0% |
Company news
Jul 7, 2026
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Horn Howard· Chief Financial Officer | Sale | 4,698 | $33.13 | $155,644.74 | filing |
| 2026-06-15 | Sanders Corazon (Corsee) D. | Sale | 2,000 | $25.05 | $50,100.00 | filing |
| 2026-06-15 | Parschauer Karah Herdman· EVP and Chief Legal Officer | Sale | 1,899 | $24.62 | $46,753.38 | filing |
| 2026-06-01 | Horn Howard· Chief Financial Officer | Sale | 4,653 | $23.77 | $110,601.81 | filing |
| 2026-05-18 | SULIMAN SHEHNAAZ | Sale | 5,740 | $25.12 | $144,188.80 | filing |
| 2026-05-14 | Fust Matthew K | Award | 7,751 | $0.00 | $0.00 | filing |
| 2026-05-14 | SULIMAN SHEHNAAZ | Award | 7,751 | $0.00 | $0.00 | filing |
| 2026-05-14 | Ray Amrit | Award | 7,751 | $0.00 | $0.00 | filing |
| 2026-05-14 | Sanders Corazon (Corsee) D. | Award | 7,751 | $0.00 | $0.00 | filing |
| 2026-05-14 | NARACHI MICHAEL | Award | 7,751 | $0.00 | $0.00 | filing |
| 2026-05-14 | WELCH DANIEL G | Award | 7,751 | $0.00 | $0.00 | filing |
| 2026-05-14 | Dunsire Deborah | Award | 7,751 | $0.00 | $0.00 | filing |
| 2026-05-05 | Crombez Eric· EVP and Chief Medical Officer | Sale | 344 | $24.96 | $8,586.24 | filing |
| 2026-05-01 | Horn Howard· Chief Financial Officer | Sale | 4,683 | $24.90 | $116,606.70 | filing |
| 2026-04-22 | Huizenga Theodore Alan· SVP, Chief Accounting Officer | Award | 20,241 | $0.00 | $0.00 | filing |
| 2026-04-16 | KAKKIS EMIL D· President & CEO | Award | 76,745 | $0.00 | $0.00 | filing |
| 2026-04-16 | Huang Dennis Karl· See Remarks | Award | 23,116 | $0.00 | $0.00 | filing |
| 2026-04-16 | Pinion John Richard· See Remarks | Award | 23,116 | $0.00 | $0.00 | filing |
| 2026-04-16 | Parschauer Karah Herdman· EVP and Chief Legal Officer | Award | 28,895 | $0.00 | $0.00 | filing |
| 2026-04-16 | Harris Erik· EVP & Chief Commercial Officer | Award | 28,895 | $0.00 | $0.00 | filing |
| 2026-04-16 | Crombez Eric· EVP and Chief Medical Officer | Award | 34,674 | $0.00 | $0.00 | filing |
| 2026-04-16 | Horn Howard· Chief Financial Officer | Award | 34,674 | $0.00 | $0.00 | filing |
| 2026-04-01 | Horn Howard· Chief Financial Officer | Sale | 4,683 | $20.97 | $98,202.51 | filing |
| 2026-03-10 | Parschauer Karah Herdman· EVP and Chief Legal Officer | Sale | 3,508 | $22.67 | $79,526.36 | filing |
| 2026-03-06 | Parschauer Karah Herdman· EVP and Chief Legal Officer | Sale | 6,018 | $21.40 | $128,785.20 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.